Minocycline Provides Neuroprotection Against N-Methyl-d-aspartate Neurotoxicity by Inhibiting Microglia1

By Tiina M. Tikka, J. Koistinaho. Journal of Immunology, 2001

595 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Neurology

View Paper: https://www.semanticscholar.org/paper/8a3fb674dd0c5da2f41ab696851c9dffbbc50611

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Linda R. Watkins
2. S. Maier
3. E. Milligan
4. Charles L Raison
5. A. Petzold
6. S. Przedborski
7. A. Bessis
8. E. Haroon

In Neurology

1. Linda R. Watkins
2. S. Maier
3. Charles L Raison
4. A. Petzold
5. E. Milligan
6. S. Przedborski
7. A. Bessis
8. E. Haroon

Citations in the corpus

• Inhibition of Microglial Activation Attenuates the Development but Not Existing Hypersensitivity in a Rat Model of Neuropathy (2003, background): “Minocycline has emerged as a potent inhibitor of microglial activation and has no direct action on astroglia or neurons (Amin et al., 1996; Tikka and Koistinaho, 2001; Tikka et al., 2001a,b).”
• Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission (2011, methodology): “We used minocyclin, an antiinflammatory agent that exerts its action by primarily preventing microglial activation (28, 29).”
• Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior (2012, background): “…production of IL-1 and NO, has been shown to inhibit p38 MAPK as well as poly(ADP-ribose) polymerase-1, which along with inhibition of NF-kB (see below), may serve as the basis for its anti-inflammatory efficacy (Tikka et al, 2001; Tikka and Koistinaho, 2001; Si et al, 2004; Alano et al, 2006).”
• Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease (2002, background): “…demonstrated in vitro (Tikka et al., 2001b) and in other experimental models of acute and chronic brain insults (Yrjanheikki et al., 1998, 1999; Tikka and Koistinaho, 2001; Tikka et al., 2001a) and results, presumably, from the blockade of p38 mitogen-activated protein kinase (Tikka et al.,…”
• Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. (2005, background): “The results are contradictory, on one side non–phosphorylated NfH (i.e. NfHSMI32 ) seems to indicate either vulnerable neurons or injured axons in diseases such as MS, glaucoma, ALS and AD [84, 93, 94, 95, 89, 90, 91].”
• Role of Microglia in Central Nervous System Infections (2004, background): “Preliminary data suggest that drugs such as minocycline (104, 352), naloxone (60, 206), dextromethorphan (209), and agents that up-regulate glutamate receptors (137, 349) have neuroprotective properties through their effects on microglial cells.”
• Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation (2005, background): “All rights reserved. traumatic brain injury (Sanchez Mejia et al., 2001), experimental autoimmune encephalomyelitis (Brundula et al., 2002; Popovic et al., 2002), and glutamate-induced neurotoxicity (Tikka and Koistinaho, 2001; Tikka et al., 2001).”